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Abstract
Hepatocellular carcinoma (HCC) and pancreatic carcinoma (PC) cells often have inherent urea cycle defects ren-
dering them auxotrophic for the amino acid L-arginine (L-arg). Most HCC and PC require extracellular sources of
L-arg and undergo cell cycle arrest and apoptosis when L-arg is restricted. Systemic, enzyme-mediated depletion of
L-arg has been investigated in mouse models and human trials. Non–human enzymes elicit neutralizing antibodies,
whereas human arginases display poor pharmacological properties in serum. Co2+ substitution of the Mn2+ metal
cofactor in human arginase I (Co-hArgI) was shown to confer more than 10-fold higher catalytic activity (kcat/Km)
and 5-fold greater stability. We hypothesized that the Co-hArgI enzyme would decrease tumor burden by systemic
elimination of L-arg in a murine model. Co-hArgI was conjugated to 5-kDa PEG (Co-hArgI–PEG) to enhance circu-
lation persistence. It was used as monotherapy for HCC and PC in vitro and in vivo murine xenografts. The mech-
anism of cell death was also investigated. Weekly treatment of 8 mg/kg Co-hArgI–PEG effectively controlled
human HepG2 (HCC) and Panc-1 (PC) tumor xenografts (P = .001 and P = .03, respectively). Both cell lines under-
went apoptosis in vitro with significant increased expression of activated caspase-3 (P < .001). Furthermore, there
was evidence of autophagy in vitro and in vivo. We have demonstrated that Co-hArgI–PEG is effective at controlling
two types of L-arg–dependent carcinomas. Being a nonessential amino acid, arginine deprivation therapy through
Co-hArgI–PEG holds promise as a new therapy in the treatment of HCC and PC.
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Introduction
Hepatocellular carcinoma (HCC) and pancreatic carcinoma (PC) are
two cancers that often depend on extracellular sources of the amino
acid L-arginine (L-arg) for survival and experience cell cycle arrest and
apoptosis in its absence [1–3]. Systemic depletion of circulating free
L-arg has been used in multiple clinical trials [2]. The native human
enzyme L-arginase I (hArgI), which uses two divalent manganese cat-
ions as an essential cofactor, is minimally active under physiological
conditions (i) because it exhibits a low catalytic activity because of a
very low saturation constant Km (=2.3 mM) at the physiological pH
of 7.4 and (ii) because, in serum, the Mn2+ ions are rapidly released
from the protein, resulting in inactivation of the enzyme with a half-
life of only 4.8 hours [4,5].
Non–human enzymes, such as arginine deiminase fromMycoplasma
arginini, display increased activity and stability under physiological
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conditions and have been under clinical evaluation for HCC, meta-
static melanoma, and small cell lung carcinoma (clinicaltrials.gov iden-
tifier: NCT01266018) [6–9]. In clinical practice, the immunogenicity
induced by non–human proteins limits the effectiveness of these en-
zymes. Specifically, blocking antibodies limits the effectiveness of non–
human enzymes. Pharmacologic immunosuppression is a theoretical
option, but it is clearly inviting multiple further problems without a
clear benefit.
Whereas patients with resectable HCC and PC have improved
survival after resection, this is an option to very few patients and still
does not offer a permanent cure in most instances. For those patients
with unresectable HCC, sorafenib has been shown to improve overall
survival rates by approximately 3 months [10]. Sorafenib constitutes
the first targeted therapy for HCC that has proven effective, albeit
with significant limitations and costs. Despite overexpression of nu-
merous antigens, PC does not have any approved targeted therapies
that significantly prolong survival, despite many therapies in clin-
ical trials [11]. It has been suggested that the reason for this is that
the extracellular stromal environment prevents targeted therapy from
reaching the cancer cells and creates a promalignant environment
[12,13]. Systemic depletion of circulating L-arg should bypass this
phenomenon by equilibrating L-arg gradients away from the tumor
directed out of the stromal microenvironment to the circulatory sys-
tem for further degradation.
The native form of hArgI has been used in small trials with short-
term success only [4]. Although there is some control of disease, most
patients quickly progress without a durable benefit. The rationale for
this is that the activity under physiological conditions (i.e., intra-
vascular in vivo) is very low, with rapid inactivation. However, a
cobalt-substituted hArgI has been demonstrated to be over 10-fold
more active than native hArgI in physiologic conditions and is much
more stable with a prolonged circulating half-life [5,14].
We hypothesized that HCC and PC xenografts would be suscep-
tible, and there would be an antitumor response to systemic L-arg
deprivation with a cobalt-substituted hArgI in a murine model.
Materials and Methods
Tumor Cell Lines, Murine Models, and Histology
The HCC cell line, HepG2, and the PC cell line, Panc-1, were
acquired from the American Type Culture Collection (Manassas,
VA) and kept in Dulbecco modified Eagle medium with 10% fetal
bovine serum and 1% penicillin/streptomycin at standard conditions.
L-Arg free Dulbecco modified Eagle medium was acquired from MP
Biomedicals, LLC (Solon, OH). Cell lines were characterized by the
Cell Line Characterization Core (MD Anderson Cancer Center,
Houston, TX). For the in vivo experiments, 3 × 106 cells were in-
jected in the right flank of nude BALB/c mice (n = 10 each cell line;
NCI Mouse Repository, Frederick, MD). Treatment began when the
tumors were palpable (approximately 4 weeks after injection) and
occurred weekly after size measurements with a digital caliper (start-
ing with week labeled “1” and volume = width2 × length). Mice in
two cages were combined and randomly chosen for the treatment
groups. Within each cell line, controls were treated with equivolume
phosphate-buffered saline by intraperitoneal (IP) injection, whereas
the treatment groups received 8 mg/kg Co-hArgI IP. All mice were
allowed standard rodent chow and water throughout the experiment
ad libitum. The chow contained approximately 25% protein by vol-
ume and less than 1% L-arg.
A body condition score (BCS) assessed the health of the mice [15],
and complete necropsy was performed to evaluate the evidence of
treatment-related toxicity and tumor response. Specimens were pre-
pared for histologic procedures by embedding in paraffin and sec-
tioning at 5 μm. The sections were stained with hematoxylin and
eosin and were examined by light microscopy. Injury to normal tis-
sues was assessed by grade (grade 1: rare, <10%; grade 2: mild, 10%-
20%; grade 3: moderate, 20%-50%; grade 4: severe, >50%) by an
expert in mammalian pathology (A.N.H.).
PEGylation of Human Co-hArgI
Co2+-substituted human hArgI was expressed in Escherichia coli,
and the protein was purified as described previously [5] with the fol-
lowing exceptions: after binding to the immobilized metal affinity
(IMAC) column, the protein was washed extensively (80-90 column
volumes) with an IMAC buffer containing 0.1% Triton 114 to re-
move endotoxin and the buffer was exchanged into 100 mM NaPO4
buffer, pH 8.3 using a 10,000 molecular weight cut off filtration
device (Millipore Corp, Billerica, MA). Using a small reaction jar,
Methoxy PEG Succinimidyl Carboxymethyl Ester 5000 MW (PEG-
5K; JenKem Technology, Allen, TX) was added to Co-hArgI at a 40:1
molar ratio and allowed to react for 1 hour at 25°C under constant
stirring. CoCl2 was added to a final concentration of 10 mM, mixed,
and heated at 50°C for 10 minutes. After centrifugation to remove any
precipitates, the PEG-5K Co-hArgI was extensively buffer exchanged
(phosphate-buffered saline [PBS] with 10% glycerol) using a 100,000
MWCO filtration device (Millipore Corp), sterilized by filtration
through a 0.2-μm syringe filter (VWR, West Chester, PA), flash-frozen
in liquid nitrogen, and stored at −80°C.
Mitochondrial Reductase Activity Analysis
HepG2 and Panc-1 cells were plated in 96-well plates at a den-
sity of 500 cells/well. Twenty-four hours later, groups of cells (n =
8) were treated with varying amounts of Co-hArgI or PBS. On days
1, 3, 5, and 7 after treatment, 100 μl of 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H -tetrazolium bromide (MTT) was added to each
well. Four hours later, the supernatant was aspirated, and 200 μl
of DMSO was added to each well. Absorbance ca. 570 nm was mea-
sured (Synergy HT; BioTeck Instruments, Inc, Winooski, VT), cor-
rected for blank DMSO, averaged for each group, and normalized to
the absorbance value of PBS controls measured at the same time.
Error bars are SEM. The 50% inhibitory concentration (IC50) was
determined by the Hill-Slope model [16].
Intracellular Protein Expression Measured with Immunoblot
In separate experiments, Panc-1 and HepG2 cells were treated
with Co-hArgI at a final concentration of 1 nM or with an equal
volume of PBS control. On days 1 and 4 after treatment, cell lysates
were obtained with cold radioimmunoprecipitation assay buffer,
incubated on ice for 30 minutes, and centrifuged at 13,000 rpm
for 30 minutes. Proteins were resolved by SDS-PAGE on a Bis-Tris
protein gel and transferred to a polyvinylidene fluoride membrane
for Western blot analysis. The membranes were incubated in 5%
nonfat dry milk for 1 hour and incubated with primary antibodies
(BD Biosciences, Franklin Lakes, NJ; or Santa Cruz Biotechnology,
Inc, Santa Cruz, CA). Next, the membranes were incubated with
peroxidase-IgG at the dilution suggested by the manufacturer (H + L
chains; Jackson Immuno Research Laboratories, West Grove, PA) and
developed using the peroxidase substrate solution (GenDEPOT, Inc,
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Barker, TX). Band intensity was determined using a high-resolution
photo scanner (CanoScan 4400F; Canon, Inc, Lake Success, NY).
Flow Cytometric Analysis
Panc-1 cells or HepG2 cells were treated with Co-hArgI (1 nM
final concentration in fresh complete media) or PBS (equivolume in
fresh complete media) 24 hours after plating. Four days later, the cells
were harvested after treatment with trypsin-EDTA (Mediatech, Inc,
Manassas, VA). Next, the cells were washed with PBS followed by
washing with Annexin buffer 1× (BD Biosciences). The cells were sus-
pended in 100 μl of buffer and stained with 7-aminoactinomycin D
(7-AAD; BD Biosciences) a fluorophore that binds to DNA in ne-
crotic cells. Cells were also stained with Annexin V conjugated to Ho-
rizon V450 (BD Biosciences) to measure external phosphatidylserine
expression. The cells were then twice washed with buffer and fixed/
permeabilized with a paraformaldehyde-based kit (CytoPerm/CytoFix;
BD Biosciences).
After permeabilization, intracellular staining was performed with
fluorophore-labeled monoclonal antibodies according to the manufac-
turers’ recommendations. A phycoerythrin-labeled antibody against the
nuclear proliferation antigen Ki-67 (BD Biosciences), a fluorescein
isothiocyanate–labeled antibody against activated caspase-3 (Santa
Cruz Biotechnology, Inc), and a monoclonal antibody against urea
cycle enzyme argininosuccinate synthetase-1 (ASS-1) conjugated to
APC-H7 (provided as a kind gift from BD Biosciences) were added
to each sample. The cells were gently mixed and then kept in the dark
for 15 minutes at 4°C.
After staining, the cells were washed and suspended in ∼200 μl of
permeabilization buffer. Typically, for each sample 20,000 cells were
analyzed by flow cytometry (LSRII Flow Cytometer; BD Biosci-
ences), and the data were analyzed with FlowJo version 8.8.6 (TreeStar,
Inc, Ashland, OR).
Activated Caspase-3 Expression in Ex Vivo Tumor Sections
Tumor sections on standard glass slides were deparaffinized by
thrice passing into xylene and were subsequently rehydrated by a se-
rial incubation in ethanol-water solutions with decreasing ethanol
concentration. Next, the slides were washed and steamed in citrate
buffer for 25 minutes, placed in methanol-hydrogen peroxide for
15 minutes, rinsed, and washed with PBS. Next, the sections were
Figure 1. After day 1, the IC50 was 0.75 ± 0.36 and 0.44 ± 0.04 nM for HepG2 (A) and Panc-1 (B) cells, respectively, based onmitochondrial
reductase activity (MTT). Flow cytometry demonstrated that HepG2 cells treated with 1 nM arginase (C) increased the apoptotic fraction
(Annexin V–positive only, P = .001) and dead cell fraction (double positive for Annexin V and 7-AAD, P = .0003) with an appropriate de-
crease in viability (double negative, P = .0001). A similar decrease in the viability of Panc-1 cells was found (D), albeit less so when com-
pared with the HepG2 cells (P = .004). Necrotic cells were identified as being Annexin V–negative, 7-AAD–positive cellular events.
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blocked with 10% solution of Tween 20 with animal serum in PBS
for 30 minutes. Anti–activated caspase-3 (cleaved large fragment) pri-
mary antibody at 1:250 dilution (Cell Signaling Technology, Inc,
Danvers, MA) was added for 2 hours at 37°C in humidified air. Sec-
tions were washed with PBS, the secondary antibody was added for
30 minutes, washed, and DAB solution was applied according to the
manufacturer’s instructions (Vector Laboratories, Burlingame, CA).
The sections were washed and counterstained with Mayer hematox-
ylin. After the final washing, the sections were sealed.
Confocal Microscopy of Ex Vivo Tumor Sections
After tumor sections were deparaffinized and rehydrated as above,
slides were placed in boiling citrate antigen retrieval (freshly prepared
10 mM citric acid, 0.05% Tween 20, pH 6.0) for 15 minutes and
blocked with 1% bovine serum albumin and 2% fetal bovine serum
in PBS for 1 hour at room temperature. Primary antibodies for
LC3B-II (1:250; Cell Signaling Technology, Inc) were diluted in
blocking solution, and sections were covered for 1.5 hours at room
temperature. The sections were thrice washed with PBS and covered
with the secondary antibody conjugated to Alexa Fluor 488 (1:500
dilution) for 1 hour in the dark at room temperature (Cell Signal-
ing Technology, Inc). Sections were then thrice washed with PBS
and stained with 300 nM DAPI for 8 minutes (Invitrogen Corp,
Carlsbad, CA). Finally, sections were washed in PBS and mounted in
aqueous mounting medium (Dako North America, Inc., Carpinteria,
CA) and sealed.
Statistics
Results are reported as mean ± SEM unless otherwise noted. Sta-
tistical significance, α, was set to P = .05. Two-tailed Student’s t test
compared differences in means between groups, whereas multiway
analysis of variation analyzed tumor volumes (SPSS version 16.0;
SPSS, Inc, Chicago, IL). Data were plotted with Sigma Plot Ver-
sion 11 (Systat Software, Inc, San Jose, CA).
Results
Co-hArgI Treatment Induces Cell Death of HepG2 and
Panc-1 Cancer Cell Lines
As shown in Figure 1, both the HCC cell line HepG2 and the PC
cell line Panc-1 demonstrated a concentration-dependent sensitivity
to treatment with Co-hArgI as determined from the decrease in mito-
chondrial reductase activity (MTT). Panc-1 cells were slightly more
sensitive than HepG2 cells to exposure of Co-hArgI (Figure 1), with
IC50 values of 0.75 ± 0.36 and 0.44 ± 0.04 nM for HepG2 and
Panc-1 cells, respectively. At concentrations less than 0.1 nM, both
cell lines had adequate nutrition to proliferate 5 to 7 days after treat-
ment compared with PBS controls on the first day. Detection of
Figure 2. Protein immunoblot demonstrated increased levels of LC3B-II after a single day of treatment with 1 nM Co-hArgI or placement
in L-arg–free medium in HepG2 cells (A). This continued but decreased by day 4 after treatment without medium replacement. Panc-1
cells initially had decreased levels of LC3B-II 1 day after treatment but increased expression by day 4. Activated (cleaved large fragment)
caspase-3 increased slightly after 1 day of treatment in HepG2 cells, whereas this was more clearly seen for Panc-1 cells 4 days after
treatment. Investigation with flow cytometry demonstrated that more individual Panc-1 cells (B) contained similar levels of ASS-1 (P =
.13), increased levels of activated caspase-3 (P = .0009), and similar Ki-67 expression (P = .66) 4 days after L-arg treatment compared
with control cells. Likewise, more HepG2 cells (C) expressed ASS-1 (P = .0001), activated caspase-3 (P < .0001), and Ki-67 (P = .0002).
All media contained 10% FBS which may contain some L-arg.
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Annexin V levels and 7-ADD staining indicated that HepG2 cells
and Panc-1 cells displayed increased rates of apoptotic cell death
4 days after treatment with 1 nM Co-hArgI (Figure 1).
There was a slight increase in activated cleaved caspase-3 in
HepG2 and Panc-1 cells after a single day of Co-hArgI treatment
based on immunoblot (Figure 2A). Whereas HepG2 cells expressed
increased amounts of LC3B-II (a marker of autophagy) after a single
day of treatments, it was not as much as the positive control (L-arg–
free media; Figure 2A). Interestingly, Panc-1 cells did not demon-
strate early increased expression of LC3B-II 1 day after treatment,
whereas it was seen 4 days after treatment (Figure 2A). On the basis
of protein immunoblot, Panc-1 cells increased the total expression of
the rate-limiting enzyme in endogenous L-arg production, ASS-1
(Figure 2A), whereas HepG2 cells show no appreciable difference
(Figure 2A) both as a function of time and treatment.
In addition to protein immunoblots that measure proteins in a
population of cells, we used flow cytometry to analyze the difference
between PBS-treated control cells and 1-nM Co-hArgI–treated cells
as a percent of the population overexpressing a given protein at the
single-cell level not the total protein expression in a sample (Figure 2,
B and C ). There were significantly more cells with increased levels of
ASS-1 protein production after Co-hArgI treatment in the HepG2
cell line (P = .0001) but not in the Panc-1 cell line (P = .13). Acti-
vated caspase-3 was increased significantly for both cell lines (P <
.0001 for HepG2 and P = .0009 for Panc-1 cells). Interestingly,
the proportion of cells expressing Ki-67 did not change for Panc-1
cells (Figure 2B, P = .66), whereas the proportion of HepG2 cells
expressing elevated levels of Ki-67 nearly tripled after Co-hArgI treat-
ment (Figure 2C ; P = .0002).
Destruction of Established HepG2 and Panc-1
Tumor Xenografts
Weekly treatment with PEG-Co-hArgI at 8 mg/kg began after
week 1 (Figure 3). Although there was no response after 1 week of
treatment, by week 3, Panc-1 tumors from treated mice grew more
slowly than tumors from control mice (Figure 3A; overall P = .03).
However, soon after treatment began in mice with HepG2 tumors,
differences in tumor volumes could be seen and continued for the
duration of the experiment (Figure 3B; overall P = .001). Of the
HepG2 tumors, two-fifths demonstrated nearly complete response
to arginase treatment (Figure 3C ). Representative sections of HepG2
tumors are shown demonstrating increased grades of necrosis (con-
trol [Figure 4A] compared to treatment [Figure 4B]), increased
amounts of cleaved caspase-3 (control [Figure 4C ] compared to treat-
ment [Figure 4D]), and increased presence of autophagosomes as
measured by LC3B-II (control [Figure 4E ] compared to treatment
[Figure 4F ]) that were seen in the tumors. Furthermore, regions of
tumor from the PBS-treated mice (Figure 4A) demonstrate larger and
presumably healthier vasculature (bright red ) not seen in the tumors
from Co-hArgI–treated mice (Figure 4B).
Toxicity Associated with Arginase Treatment
Mice treated with greater than 15-mg/kg Co-hArgI demonstrated
significant toxicity (weight loss, hunch posture, lethargy) requiring
euthanasia in accordance with the humane treatment of animals. Full
necropsies were performed, and the only evidence of histologic abnor-
mality was bone marrow devastation in a concentration-dependent
manner (Figure 5A). Low-dose Co-hArgI (<10 mg/kg) and control
mice did not demonstrate bone marrow injury (Figure 5B). Weight
loss, as well, was dependent on the dose of arginase received (Fig-
ure 5C ). No other major organ such as brain, heart, lung, kidney, liver,
or gastrointestinal tract demonstrated any insults on gross examination
or histologic evaluation.
Discussion
We have demonstrated that Co-hArgI affects the growth of human
HCC and PC xenografts in a murine model. The rationale for systemic
arginine deprivation therapy for HCC or PC is not a new idea, but
the difficulty has been doing so in an effective and nonimmunogenic
Figure 3. (A) Panc-1 subcutaneous xenografts in nude BALB/c
mice demonstrated decreased tumor volume due to treatment
with 8 mg/kg Co-hArgI–PEG (P = .03). (B) Likewise, HepG2 subcu-
taneous xenografts also demonstrated significantly smaller tu-
mors, but they did so within 1 week of treatment (P = .001). (C)
At the end of the experiment, PEG–Co-hArgI–treated tumors were
much smaller as exemplified in the HepG2 tumors.
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manner [7,17]. Other therapies have failed because they use foreign
proteins inducing an immunogenic response, or they are enzymes
that are minimally active in physiologic intravascular conditions. We
have solved these problems by using a minimally engineered human
enzyme with improved kinetics and stability that should eliminate or
greatly reduce host immunogenic responses. Formal toxicity studies
will be performed in the near future to verify this. Clearly, individual
patient variations may limit the effectiveness of Co-hArgI, but we be-
lieve that starting with a stabilized human enzyme is promising. We
estimate that the toxicity seen in vivo occurs at more than 200× the
in vitro concentration used herein. It is inappropriate to assume that
human toxicity data will be the same as mouse; however, these data are
suggestive that there will be a reasonable therapeutic window for clin-
ical trials.
Small case reports that demonstrate effectiveness of endogenous ar-
ginase reassure that the minimally engineered Co-hArgI should be ef-
fective at depleting systemic L-arg levels [18]. Furthermore, depleting
systemic L-arg has resulted in decreased HCC tumor burdens in mul-
tiple human and animal studies with multiple other enzymes [4,7,18].
The principle of this therapy remains the same, but identifying the
least toxic and least immunogenic modality has been the major chal-
lenge. The toxicity seen in mice herein and the duration to recovery
(i.e., normalization of BCS scores) limited the treatment interval to
weekly while permitting some L-arg reconstitution in the serum from
dietary sources (data not shown). Clinical effectiveness will determine
the appropriate balance of treatment dose, interval, and adverse events.
The differences in mitochondrial activity (MTT assay), decrease
in viability (as defined by Annexin V and propidium iodide double
Figure 4. Although there is some necrosis (*) in HepG2 tumors from mice treated with PBS controls (A; hematoxylin and eosin stain,
bright red areas are intravascular blood), there was significantly higher grades of necrosis in the tumors from arginase-treated mice (B).
Likewise, a few cells in control tumors expressed activated caspase-3 (C; immunohistochemistry [IHC]), although significantly more
cells expressed activated caspase-3 after Co-hArgI treatment (D). Finally, tumors from control-treated mice demonstrated far fewer
autophagosomes (E; immunofluorescence [IF]; green label is LC3B-II, whereas blue label is DAPI) than tumors from arginase-treated
mice (F). Larger nuclei (blue) are seen with Co-hArgI treatment (D, F).
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positivity), and caspase-3 expression demonstrate some variability in
cellular death at the single-cell resolution (Figures 1 and 2). We theo-
rize that this is due to the balance of availability of L-arg and cellular
responses to maintain homeostasis (i.e., autophagy seen in the L-arg–
free media). In addition, cells that are more sensitive to L-arg depriva-
tion respond sooner, whereas cells able to maintain homeostasis do not
respond as quickly.
The observed slight induction of cleaved caspase-3 and increased
presence of autophagosomes are not unexpected. Discrepancies be-
tween the immunoblot and flow cytometric data suggest that sub-
populations of cells exist that respond differently at the individual
cell level. Both activated/cleaved caspase-3 and autophagosome pro-
ductions have been previously demonstrated during amino acid depri-
vation therapy, in general, and L-arg deprivation specifically [9,14,19].
Interestingly, other groups have investigated a caspase-independent
pathway toward cell death via autophagy in prostate cancer xenografts
treated with L-arg deprivation therapy [20]. This supports studies
suggesting a role for selective autophagy in cancer development [21].
An inadequate supply of circulating L-arg coupled with an inability
to synthesize more may increase genomic instability and aberrant
signaling pathways [21]. The results here neither confirm nor con-
tradict this finding because we did not investigate these pathways as
deeply as the other studies. However, it is interesting that we found
evidence of both cleaved caspase-3 and autophagosomes in vitro and
in vivo. HepG2 cells demonstrated increased levels of LC3B-II more
so than Panc-1 cells (Figure 2A). This suggests that various cancers
may succumb to treatment through different pathways, something
under active research. Simultaneously, Panc-1 cells demonstrated rela-
tively more activated caspase-3 than HepG2 cells 4 days after treat-
ment (Figure 2A). It is likely that bioengineered Co-hArgI will be
useful as part of a multimodal therapy for HCC or PC. This is es-
pecially true as new therapies develop based on the modulation of
multiple pathways (i.e., caspase cascade or autophagy), where the com-
bination may be effective in treating many types of susceptible solid
organ malignancies.
The increase in Ki-67 expression in vitro and increased nuclear size
in vivo is very interesting. In humans, multiple studies have dem-
onstrated correlations between nuclear size (morphometry) and in-
creased Ki-67 expression in solid organ malignancies similar to those
demonstrated here (Figures 2C and 4F ) [22–25]. We expected that
cellular processes would decrease during L-arg deprivation and result
in decreased Ki-67. However, we theorize that continued proliferation
despite decreased L-arg reserves is characteristic of L-arg auxotrophy
in this model. The total cellular mass is decreased based on MTT data
in vitro and reduced tumor sizes in vivo. Therefore, we believe that
HepG2 cells continue active metabolic pathways in the attempt to ac-
quire more L-arg through autophagy but cannot do so and eventually
die. This somewhat unexpected correlation between Ki-67 expression
and autophagy has been demonstrated in human gastrointestinal can-
cers [26], as has the correlation between activated/cleaved caspase-3
and LC3B-II expression [27]. Panc-1 cells, however, do not increase
their intrinsic metabolic rates and hence are able to live longer (and
hence, tumors remain larger), whereas mitochondrial reductase activity
remains low overall. This is consistent with a G0/G1 block that we
have previously demonstrated [14].
It seems from ASS-1 expression levels that at least some Panc-1
and HepG2 cells are attempting to replenish L-arg levels. However,
this occurs several enzymatic steps upstream of ASS-1–mediated
synthesis of argininosuccinate from L-citrulline, aspartate, and ATP.
HepG2 cells (and other HCC models) have previously demonstrated
to be particularly sensitive to L-arg depletion with arginase treat-
ment as opposed to arginine deiminase treatment because those cells
cannot consistently and simultaneously produce sufficient amounts
of both ASS-1 and ornithine transcarbamylase for L-arg production
[1,3,28]. Thus far, L-arg auxotrophy in some pancreatic tumors
seems to be primarily a function of ASS-1 down-regulation, so it is
Figure 5. Arginase-related toxicity was found in mice treated at doses of 15 mg/kg or greater. On necropsy, the only evidence of normal
tissue toxicity was massive bone marrow devastation (A), whereas control bone marrow remained normal (B). In addition, weight loss
was measured as a function of dose-dependent toxicity (0-32 mg/kg, n= 5 each) after IP injection of L-arg. The greatest observed weight
loss occurred 4 days after treatment (C). The 16- and 32-mg/kg groups had a BCS of 1 and were killed for humane reasons. The mice in
the 8-mg/kg group had a BCS score of 2 to 3 and regained their original body mass in an additional 2 to 3 days.
144 Arginase for Hepatocellular and Pancreatic Carcinoma Glazer et al. Translational Oncology Vol. 4, No. 3, 2011
interesting that unlike previous reports, we were able to observe some
ASS-1 protein in Panc-1 cells [1]. Furthermore, we describe that, for
our control Panc-1 cells, depletion of all arginine in the medium re-
sults in increased ASS-1 production over time not seen in HepG2
cells. The discrepancy between previous reports and data herein
may relate to the degree of insult induced by the arginine deprivation
therapy. Finally, the level of ASS-1 production may determine how
subpopulations of cells respond in terms of apoptosis, autophagy,
and/or cell death.
In vitro, the potent IC50 values of Co-hArgI toward both HepG2
and Panc-1 cells are similar, suggesting that the urea cycle is not suffi-
ciently intact in either tumor type to produce enough L-arg internally
for continued growth in the face of extrinsic arginine depletion. We
theorize that the discrepancy between population immunoblot mea-
surements of ASS-1 and individual cell flow cytometric measurements
suggests that there are variations in cell subpopulations. Likely, nonspe-
cific amino acid transporters allow for L-arg to be “shared” in the cell
cultures, decreasing the need for ASS-1 in some cell subpopulations.
In vivo, however, Co-hArgI–PEG shows a more robust response
toward HepG2 than Panc-1. It is likely that the slower metabolism
of Panc-1 cells in the in vivo mouse xenograft model allows them to
withstand the periods of L-arg depletion longer than the more met-
abolically active HepG2 cells. However, modulation in Co-hArgI–
PEG dosing in mice may allow longer L-arg depletion times, but this
is precluded by toxic bone marrow suppression effects at very high
doses of Co-hArgI–PEG in mice with unclear consequences in hu-
mans. We suspect that the more resilient Panc-1 tumors will require
longer L-arg depletion times than can be safely withstood in mice. In
humans, however, long-term L-arg depletion by arginine deaminase
has been well tolerated, with the exception that neutralizing anti-
bodies eventually develop [7], thus diminishing the effectiveness of
this mycoplasmic enzyme in the long term.
A major drawback to this study is that only two cell lines were
investigated. We chose to investigate two specific cancers that have
very few effective therapies. Multiple studies from in vitro analyses to
phase 2 clinical trials have demonstrated that arginine deprivation
therapy is effective, albeit for short-term treatments only. However,
we sought to investigate the use of a novel, bioengineered human
enzyme. The fact that it was effective at safe concentrations in vivo
suggests that further studies are warranted, although we only used
two cell lines. In addition, further investigation requires determining
whether autophagy or apoptosis is the primary means of cell demise.
Likewise, investigations regarding these complex-signaling path-
ways are needed. Whereas there is evidence in the literature of both
processes, and evidence herein to the same, much still needs to be
elucidated as to which is most important and methods to combine
treatments for maximum cancer therapy.
In summary, we have demonstrated the first in vivo data regard-
ing a highly active, cobalt-substituted human arginase for the treat-
ment of HCC and PC. The therapy was well tolerated in two murine
xenograft models, with promising results. Further studies are under-
way with HCC, PC, and other cancer models with plans for future
clinical trials.
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